logo-loader

Shield Therapeutics CEO says all efforts are on securing US partner for Feraccru

Published: 14:00 22 May 2020 BST

Shield Therapeutics PLC’s (LON:STX) chief executive Tim Watts caught up with Proactive's Andrew Scott on the back of its 2019 results.

He says that finding a US partner for its iron deficiency drug Accrufer is the top priority for 2020.

Shield already has commercial agreements in Europe and China for the drug, which is known as Feraccru outside the US.

Shield Therapeutics' pricing will be "key metric" - Proactive Research Analyst

Proactive Research Analyst Robin Davison speaks to Thomas Warner after publishing a new research note on iron defiency-focused commercial-stage specialty pharmaceutical company Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) Davison gives an overview of what readers can expect from the note,...

on 3/10/23